Treatment of hemiplegic migraine with triptans |
| |
| Authors: | V. Artto,M. Nissilä ,M. Wessman,A. Palotie,M. Fä rkkilä , M. Kallela |
| |
| Affiliation: | Department of Neurology, Helsinki University Central Hospital, Finland;;Turku Headache Center, Finland;;The Finnish Genome Center, Helsinki, Finland;;Folkhälsan Research Center, Helsinki, Finland;;The Broad Institute of MIT and Harvard, Cambridge, MA, USA;;and Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland |
| |
| Abstract: | The objective of this study was to investigate the efficacy, safety and tolerability of triptans in patients who suffer from familial or sporadic hemiplegic migraine. Seventy-six subjects had used triptans at least once as an abortive treatment. Average triptan response was 6.9 (SD ±3.1) and adverse event severity 4.9 (SD ±3.3) on a scale from 0 to 10 (no response or side effect 0, excellent response or unbearable side effects 10). None of the patients had an ischaemic stroke or a heart attack. One patient reported prolonged neurological symptoms, related to a single dose of rizatriptan, but there were no pathological findings in several MRI-scans. Triptans seem to be safe and effective treatment for most hemiplegic migraine patients. |
| |
| Keywords: | hemiplegic migraine treatment triptans |
|
|
